Penumbra (PEN) Change in Accured Expenses (2014 - 2026)
Penumbra's (PEN) quarterly Change in Accured Expenses came in at $16.9 million in Q1 2026, up 2851.74% year-on-year from $574000.0 in Q1 2025, and up 716.14% on a QoQ basis from $2.1 million in Q4 2025.
Penumbra (PEN) Change in Accured Expenses (2014 - 2026) Analysis & Trends
Penumbra (PEN) has 13 years of Change in Accured Expenses data on file, last reported at $16.9 million in Q1 2026.
- On a quarterly basis, Change in Accured Expenses rose 2851.74% year-over-year to $16.9 million in Q1 2026; TTM through Mar 2026 was $29.3 million, a 87.05% increase from a year earlier, with the FY2025 full-year figure at $12.9 million, down 8.16% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $16.9 million, up from $2.1 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for PEN reached as high as $16.9 million in Q1 2026 and fell as low as -$9.5 million in Q3 2022.
- Historically, Change in Accured Expenses has averaged $3.6 million across 5 years, with a median of $2.1 million in 2025.
- Across the five-year window, Change in Accured Expenses sank 298.47% in 2022 and jumped 5575.86% in 2025, its largest moves.
- Year by year, Change in Accured Expenses stood at $4.4 million in 2022, then jumped by 50.15% to $6.6 million in 2023, then soared by 111.4% to $13.9 million in 2024, then plunged by 85.06% to $2.1 million in 2025, then surged by 716.14% to $16.9 million in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were $16.9 million in Q1 2026, $2.1 million in Q4 2025, and $5.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -654.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 123.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -512.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -347.10 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 145.10 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 21.07 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -250.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Penumbra | 12.48 Bn | 11.87 Bn | 253.41 Mn | 16.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 16.94 Mn |
| Mar 31, 2026 | 16.94 Mn |
| Dec 31, 2025 | 2.08 Mn |
| Dec 31, 2025 | 2.08 Mn |
| Sep 30, 2025 | 5.32 Mn |
| Sep 30, 2025 | 5.32 Mn |
| Jun 30, 2025 | 4.94 Mn |
| Jun 30, 2025 | 4.94 Mn |
| Mar 31, 2025 | 574,000.00 |
| Mar 31, 2025 | 574,000.00 |
| Dec 31, 2024 | 13.89 Mn |
| Dec 31, 2024 | 13.89 Mn |
| Sep 30, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 87,000.00 |
| Jun 30, 2024 | 87,000.00 |
| Mar 31, 2024 | -1.02 Mn |
| Mar 31, 2024 | -1.02 Mn |
| Dec 31, 2023 | 6.57 Mn |
| Dec 31, 2023 | 6.57 Mn |